参考文献/References:
[1] Powell LW,Seckington RC,Deugnier Y. Haemochromatosis[J].Lancet,2016,388(10045):706-716.
[2] Pantopoulos K. Inherited disorders of iron overload[J].Front Nutr,2018,5:103.
[3] Diez-Lopez C,Comin-Colet J,Gonzalez-Costello J. Iron overload cardiomyopathy:from diagnosis to management[J].Curr Opin Cardiol,2018,33(3):334-340.
[4] Aronow WS. Management of cardiac hemochromatosis[J].Arch Med Sci,2018,14(3):560-568.
[5] Kremastinos DT,Farmakis D,Aessopos A,et al. Beta-thalassemia cardiomyopathy:history,present considerations,and future perspectives[J].Circ Heart Fail,2010,3(3):451-458.
[6] Pennell DJ,Udelson JE,Arai AE,et al. Cardiovascular function and treatment in beta-thalassemia major:a consensus statement from the American Heart Association[J].Circulation,2013,128(3):281-308.
[7] Farmakis D,Triposkiadis F,Lekakis J,et al. Heart failure in haemoglobinopathies:pathophysiology,clinical phenotypes,and management[J].Eur J Heart Fail,2017,19(4):479-489.
[8] Tsushima RG,Wickenden AD,Bouchard RA,et al. Modulation of iron uptake in heart by L-type Ca2+ channel modifiers:possible implications in iron overload[J].Circ Res,1999,84(11):1302-1309.
[9] Ke Y,Chen YY,Chang YZ,et al. Post-transcriptional expression of DMT1 in the heart of rat[J].J Cell Physiol,2003,196(1):124-130.
[10] Kumfu S, Chattipakorn S, Srichairatanakool S,et al. T-type calcium channel as a portal of iron uptake into cardiomyocytes of beta-thalassemic mice[J].Eur J Haematol,2011,86(2):156-166.
[11] Gordan R,Wongjaikam S,Gwathmey JK,et al. Involvement of cytosolic and mitochondrial iron in iron overload cardiomyopathy:an update[J].Heart Fail Rev,2018,23(5):801-816.
[12] Wongjaikam S,Kumfu S,Khamseekaew J,et al. Restoring the impaired cardiac calcium homeostasis and cardiac function in iron overload rats by the combined deferiprone and N-acetyl cysteine[J].Sci Rep,2017,7:44460.
[13] Fraidenburg DR,Machado RF.Pulmonary hypertension associated with thalassemia syndromes[J].Ann N Y Acad Sci,2016,1368(1):127-139.
[14] Stockwell BR,Friedmann Angeli JP,Bayir H,et al. Ferroptosis: a regulated cell death nexus linking metabolism,redox biology,and disease[J].Cell,2017,171(2):273-285.
[15] Wang H,An P,Xie E,et al. Characterization of ferroptosis in murine models of hemochromatosis[J].Hepatology,2017,66(2):449-465.
[16] Fang X,Wang H,Han D,et al. Ferroptosis as a target for protection against cardiomyopathy[J].Proc Natl Acad Sci U S A,2019,116(7):2672-2680.
[17] Pietrangelo A. Hereditary hemochromatosis—a new look at an old disease[J].N Engl J Med,2004,350(23):2383-2397.
[18] Kirk P,Roughton M,Porter JB,et al. Cardiac T2* magnetic resonance for prediction of cardiac complications in thalassemia major[J].Circulation,2009,120(20):1961-1968.
[19] Aessopos A,Farmakis D,Hatziliami A,et al. Cardiac status in well-treated patients with thalassemia major[J].Eur J Haematol,2004,73(5):359-366.
[20] Aessopos A,Farmakis D,Deftereos S,et al. Thalassemia heart disease:a comparative evaluation of thalassemia major and thalassemia intermedia[J].Chest,2005,127(5):1523-1530.
[21] di Odoardo LAF,Giuditta M,Cassinerio E,et al. Myocardial deformation in iron overload cardiomyopathy:speckle tracking imaging in a beta-thalassemia major population[J].Intern Emerg Med,2017,12(6):799-809.
[22] Rozwadowska K,Danilowicz-Szymanowicz L,Fijalkowski M,et al. Can two-dimensional speckle tracking echocardiography be useful for left ventricular assessment in the early stages of hereditary haemochromatosis?[J].Echocardiography,2018,35(11):1772-1781.
[23] Anderson LJ, Holden S,Davis B,et al. Cardiovascular T2-star(T2*) magnetic resonance for the early diagnosis of myocardial iron overload[J].Eur Heart J,2001,22(23):2171-2179.
[24] Modell B,Khan M,Darlison M,et al. Improved survival of thalassaemia major in the UK and relation to T2* cardiovascular magnetic resonance[J].J Cardiovasc Magn Reson,2008,10:42.
[25] Alam MH, Auger D, McGill LA,et al. Comparison of 3 T and 1.5 T for T2* magnetic resonance of tissue iron[J].J Cardiovasc Magn Reson,2016,18(1):40.
[26] Pepe A,Meloni A,Rossi G,et al. Cardiac complications and diabetes in thalassaemia major:a large historical multicentre study[J].Br J Haematol,2013,163(4):520-527.
[27] Liu JM,Liu A,Leal J,et al. Measurement of myocardial native T1 in cardiovascular diseases and norm in 1291 subjects[J].J Cardiovasc Magn Reson,2017,19(1):74.
[28] Hanneman K,Nguyen ET,Thavendiranathan P,et al. Quantification of myocardial extracellular volume fraction with cardiac MR imaging in thalassemia major[J].Radiology,2016,279(3):720-730.
[29] Alam MH,Auger D,Smith GC,et al. T1 at 1.5T and 3T compared with conventional T2* at 1.5T for cardiac siderosis[J].J Cardiovasc Magn Reson,2015,17:102.
[30] Kremastinos DT,Farmakis D. Iron overload cardiomyopathy in clinical practice[J].Circulation,2011,124(20):2253-2263.
[31] Olivieri NF,Nathan DG,MacMillan JH,et al. Survival in medically treated patients with homozygous beta-thalassemia[J].N Engl J Med,1994,331(9):574-578.
[32] Casale M,Meloni A,Filosa A,et al. Multiparametric cardiac magnetic resonance survey in children with thalassemia major: a multicenter study[J].Circ Cardiovasc Imaging,2015,8(8):e003230.
[33] Bacon BR,Adams PC,Kowdley KV,et al. Diagnosis and management of hemochromatosis:2011 practice guideline by the American Association for the Study of Liver Diseases[J].Hepatology,2011,54(1):328-343.
[34] de Buck E,Pauwels NS,Dieltjens T,et al. Is blood of uncomplicated hemochromatosis patients safe and effective for blood transfusion?A systematic review[J].J Hepatol,2012,57(5):1126-1134.
[35] Winters AC,Tremblay D,Arinsburg S,et al. Reassessing the safety concerns of utilizing blood donations from patients with hemochromatosis[J].Hepatology,2018,67(3):1150-1157.
[36] Tauchenova L,Krizova B,Kubanek M,et al. Successful treatment of iron-overload cardiomyopathy in hereditary hemochromatosis with deferoxamine and deferiprone[J].Can J Cardiol,2016,32(12):1574.e1-1574.e3.
[37] Ong SY,Gurrin LC,Dolling L,et al. Reduction of body iron in HFE-related haemochromatosis and moderate iron overload(Mi-Iron):a multicentre, participant-blinded,randomised controlled trial[J].Lancet Haematol,2017,4(12):e607-e614.
[38] Hershko C. Oral iron chelators:new opportunities and new dilemmas[J].Haematologica,2006,91(10):1307-1312.
[39] Glickstein H,El RB,Shvartsman M,et al. Intracellular labile iron pools as direct targets of iron chelators:a fluorescence study of chelator action in living cells[J].Blood,2005,106(9):3242-3250.
[40] Glickstein H, El RB, Link G ,et al. Action of chelators in iron-loaded cardiac cells:accessibility to intracellular labile iron and functional consequences[J].Blood,2006,108(9):3195-3203.
[41] Pennell DJ, Berdoukas V, Karagiorga M,et al. Randomized controlled trial of deferiprone or deferoxamine in beta-thalassemia major patients with asymptomatic myocardial siderosis[J].Blood,2006,107(9):3738-3744.
[42] Pennell DJ, Porter JB, Piga A,et al. A 1-year randomized controlled trial of deferasirox vs deferoxamine for myocardial iron removal in beta-thalassemia major (CORDELIA)[J].Blood,2014,123(10):1447-1454.
[43] Pennell DJ, Porter JB, Piga A,et al. Sustained improvements in myocardial T2* over 2 years in severely iron-overloaded patients with beta thalassemia major treated with deferasirox or deferoxamine[J].Am J Hematol,2015,90(2):91-96.
[44] Tanner MA, Galanello R, Dessi C,et al. A randomized, placebo-controlled, double-blind trial of the effect of combined therapy with deferoxamine and deferiprone on myocardial iron in thalassemia major using cardiovascular magnetic resonance[J].Circulation,2007,115(14):1876-1884.
[45] Alpendurada F, Smith GC, Carpenter JP,et al. Effects of combined deferiprone with deferoxamine on right ventricular function in thalassaemia major[J].J Cardiovasc Magn Reson,2012,14:8.
[46] Carpenter JP,Roughton M,Pennell DJ. International survey of T2* cardiovascular magnetic resonance in beta-thalassemia major[J].Haematologica,2013,98(9):1368-1374.
[47] Fernandes JL,Loggetto SR,Verissimo MP,et al. A randomized trial of amlodipine in addition to standard chelation therapy in patients with thalassemia major[J].Blood,2016,128(12):1555-1561.
[48] Eghbali A,Kazemi H,Taherahmadi H,et al. A randomized, controlled study evaluating effects of amlodipine addition to chelators to reduce iron loading in patients with thalassemia major[J].Eur J Haematol,2017,99(6):577-581.
相似文献/References:
[1]丁娟,刘地川.心力衰竭与线粒体功能障碍的研究进展[J].心血管病学进展,2016,(1):84.[doi:10.16806/j.cnki.issn.1004-3934.2016.01.022]
DING Juan,LIU Dichuan.Research Progress of Heart Failure and Mitochondrial Dysfunction[J].Advances in Cardiovascular Diseases,2016,(5):84.[doi:10.16806/j.cnki.issn.1004-3934.2016.01.022]
[2]罗秀林,综述,张烁,等.肾动脉去交感神经术治疗心力衰竭——希望还是炒作[J].心血管病学进展,2016,(3):268.[doi:10.16806/j.cnki.issn.1004-3934.2016.03.013]
LUO Xiulin,ZHANG Shuo.Renal Sympathetic Denervation for Heart Failure—Hopes or Hypes[J].Advances in Cardiovascular Diseases,2016,(5):268.[doi:10.16806/j.cnki.issn.1004-3934.2016.03.013]
[3]查凤艳,综述,覃数,等.心源性恶病质发病机制的研究进展[J].心血管病学进展,2016,(3):282.[doi:10.16806/j.cnki.issn.1004-3934.2016.03.017]
ZHA Fengyan,QIN Shu.Advances in Pathogenesis of Cardiac Cachexia[J].Advances in Cardiovascular Diseases,2016,(5):282.[doi:10.16806/j.cnki.issn.1004-3934.2016.03.017]
[4]李慧,综述,齐国先,等.老年射血分数保留的心功能不全研究进展[J].心血管病学进展,2016,(4):354.[doi:10.16806/j.cnki.issn.1004-3934.2016.04.007]
LI Hui,QI Guoxian.Research Progress of Heart Failure with Preserved Ejection Fraction in Elderly People[J].Advances in Cardiovascular Diseases,2016,(5):354.[doi:10.16806/j.cnki.issn.1004-3934.2016.04.007]
[5]亢玉,综述,张庆,等.二尖瓣瓣叶在功能性二尖瓣反流发生机制中的角色[J].心血管病学进展,2016,(4):376.[doi:10.16806/j.cnki.issn.1004-3934.2016.04.013]
KANG Yu,ZHANG Qing.Role of Mitral Leaflets in Pathogenesis of Functional Mitral Regurgitation[J].Advances in Cardiovascular Diseases,2016,(5):376.[doi:10.16806/j.cnki.issn.1004-3934.2016.04.013]
[6]史秀莉,张庆,喻鹏铭.心力衰竭患者运动训练方式及其疗效的研究进展[J].心血管病学进展,2015,(5):535.[doi:10.3969/j.issn.1004-3934.2015.05.003]
SHI Xiuli,ZHANG Qing,YU Pengming.Exercise Training Modalities and Their Treatment Effects on
Patients with Heart Failure[J].Advances in Cardiovascular Diseases,2015,(5):535.[doi:10.3969/j.issn.1004-3934.2015.05.003]
[7]郭彩艳 靳春荣.腺苷药物在心血管疾病诊治中的应用进展[J].心血管病学进展,2019,(7):1011.[doi:10.16806/j.cnki.issn.1004-3934.2019.07.012]
GUO CaiyanJIN Chunrong.Progress in the Application of Adenosine Drugs in the Diagnosis and Treatment of Cardiovascular Diseases[J].Advances in Cardiovascular Diseases,2019,(5):1011.[doi:10.16806/j.cnki.issn.1004-3934.2019.07.012]
[8]熊卓超,陈康玉,严激.无创血流动力学评价在心力衰竭中的应用进展[J].心血管病学进展,2019,(6):923.[doi:10.16806/j.cnki.issn.1004-3934.2019.06.021]
XIONG Zhuochao,CHEN Kangyu,YAN Ji.Application Progress of Noninvasive Hemodynamic Evaluation in Heart Failure[J].Advances in Cardiovascular Diseases,2019,(5):923.[doi:10.16806/j.cnki.issn.1004-3934.2019.06.021]
[9]吴洋.左室心肌致密化不全的心脏磁共振诊断[J].心血管病学进展,2019,(5):673.[doi:10.16806/j.cnki.issn.1004-3934.2019.05.004]
WU Yang.Diagnosis of Left Ventricular Non-compaction Cardiomyopathy With Cardiac Magnetic Resonance Imaging[J].Advances in Cardiovascular Diseases,2019,(5):673.[doi:10.16806/j.cnki.issn.1004-3934.2019.05.004]
[10]徐源蔚 陈玉成.心脏磁共振在检测自身免疫性风湿疾病心脏受累中的应用进展[J].心血管病学进展,2019,(5):676.[doi:10.16806/j.cnki.issn.1004-3934.2019.05.005]
XU Yuanwei,CHEN Yucheng.Advances in the Application of Cardiac Magnetic Resonance in Detecting Cardiac Involvement in Autoimmune Rheumatic Disease[J].Advances in Cardiovascular Diseases,2019,(5):676.[doi:10.16806/j.cnki.issn.1004-3934.2019.05.005]